United Therapeutics (STU:UTH) ROCE % : 25.84% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is United Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. United Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2024 was 25.84%.

United Therapeutics ROCE % Historical Data

The historical data trend for United Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics ROCE % Chart

United Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

16.42

13.84

19.16

21.81

24.84

United Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															19.44	27.51	25.59	25.88	25.84

United Therapeutics ROCE % Calculation

United Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	1510.715	/	( ( (6572.139 - 737.635)	+	(7032.62 - 704.886) )	/ 2 )
	=	1510.715	/	( (5834.504	+	6327.734)	/ 2 )
	=	1510.715	/	6081.119
	=	24.84 %

United Therapeutics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	1544.808	/	( ( (6417.913 - 786.933)	+	(7032.62 - 704.886) )	/ 2 )
	=	1544.808	/	( ( 5630.98	+	6327.734 )	/ 2 )
	=	1544.808	/	5979.357
	=	25.84 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

United Therapeutics (STU:UTH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

United Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of United Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (STU:UTH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany U2TH34:Brazil

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Headlines

No Headlines